Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol Myers Squibb reported stronger-than-expected earnings for the fourth quarter and full year of 2024, but rising ...

Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $62 from $60 and keeps an Equal Weight rating on the shares. While ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of ...

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.